MHRA (UK)
OTHER
Class 4 Medicines Defect Notification: Blumont Pharma Limited, Ocumont Eye Ointment 1% w/w, EL(26)A/03
Published: 1/27/2026Detected: 3/22/2026
Summary preview
Reports a significant labeling defect regarding the absence of Braille on the outer carton of a specific batch of Ocumont Eye Ointment 1% w/w, which could impact accessibility for visually impaired patients.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/4010/1/2026
- Field Safety Notices: 21 to 25 September 20269/29/2026
- MHRA Safety Roundup: September 20269/29/2026
- Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/399/23/2026
- Field Safety Notices: 14 to 18 September 20269/23/2026